Resmed Inc. (NYSE:RMD) Beats Q4 2025 Revenue and EPS Estimates Despite Muted Market Reaction

Resmed Inc. (NYSE:RMD) Reports Q4 2025 Earnings: Revenue and EPS Beat Estimates, Market Reaction Muted

Resmed Inc. (NYSE:RMD) released its fourth-quarter fiscal 2025 earnings, posting revenue and earnings per share (EPS) that exceeded analyst expectations. Despite the beat, the stock saw a slight decline in after-hours trading, suggesting a tempered market response.

Key Earnings Highlights

• Revenue: The company reported $1.35 billion in revenue for Q4 2025, surpassing the consensus estimate of $1.34 billion. This represents a 10% year-over-year increase.
• Earnings Per Share (EPS): Resmed delivered EPS of $2.55, beating the estimated $2.50.
• Operating Profit: Both GAAP and non-GAAP operating profits rose by 19%, indicating strong operational efficiency.
• Cash Flow: Operating cash flow came in at $539 million, reinforcing the company’s financial health.
• Dividend Increase: The company announced a quarterly dividend hike, signaling confidence in its cash generation capabilities.

Market Reaction

Despite the earnings beat, Resmed’s stock dipped approximately 1.08% in after-hours trading. This muted reaction could reflect:

• High Expectations: Investors may have already priced in strong performance, leaving little room for upside surprise.
• Macro or Sector Sentiment: Broader market conditions or sector-specific concerns could be weighing on the stock.
• Forward Guidance Uncertainty: While the press release did not provide explicit forward-looking guidance, analysts have already set expectations for fiscal 2026, with full-year revenue projected at $5.58 billion and Q1 2026 revenue estimated at $1.33 billion.

Analyst Estimates vs. Performance

Resmed’s ability to consistently outperform estimates is notable, but the market’s reaction suggests investors are looking for more than just a beat—they may be assessing sustainability, competitive positioning, or macroeconomic risks.

Looking Ahead

Analysts expect:

• Q1 2026 Revenue: $1.33 billion
• Full-Year 2026 Revenue: $5.58 billion
• Full-Year 2026 EPS: $10.58

Given the company’s strong cash flow and dividend increase, Resmed appears well-positioned for steady growth, though the market’s cautious stance indicates a wait-and-see approach.

For more detailed earnings estimates and historical performance, visit Resmed’s earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.